(Q34503137)

2 August 2017

1 reference

title

Secondary progressive multiple sclerosis: current knowledge and future challenges (English)

1 reference

secondary progressive multiple sclerosis

2 August 2017

main subject

0 references

0 references

3

1 reference

2 August 2017

Massimo Filippi

6

0 references

Ludwig Kappos

series ordinal

4

object named as

Ludwig Kappos

1 reference

2 August 2017

5

Giancarlo Comi

1 reference

2 August 2017

Marco Rovaris

1

1 reference

2 August 2017

Christian Confavreux

series ordinal

2

1 reference

2 August 2017

publication date

1 April 2006

1 reference

2 August 2017

1 reference

2 August 2017

volume

5

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

343-354

1 reference

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

EDMUS, a European database for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

A prospective study on the prognosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Early prognostic factors for disability in multiple sclerosis, a European multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Relapses and progression of disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Primary and secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

A comparison of the pathology of primary and secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Immunopathology of secondary-progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Distinct chemokine receptor and cytokine expression profile in secondary progressive MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Immunological patterns identifying disease course and evolution in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Major differences in the dynamics of primary and secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Primary and transitional progressive MS: a clinical and MRI cross-sectional study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Assessing information in T2-weighted MRI scans from secondary progressive MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Ring-enchancement in multiple sclerosis: marker of disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

A magnetization transfer histogram study of normal-appearing brain tissue in MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Optimizing the association between disability and biological markers in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Inflammation and atrophy in multiple sclerosis: MRI associations with disease course

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

A spinal cord MRI study of benign and secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Spinal cord atrophy and disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Spinal cord atrophy and disability in MS: A longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Whole brain volume changes in patients with progressive MS treated with cladribine.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

The effect of cladribine on T(1) 'black hole' changes in progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Diffusion MRI in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Magnetization transfer imaging to monitor the evolution of MS: A 1-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Magnetization transfer ratio histogram analysis of normal-appearing gray matter and normal-appearing white matter in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

A conventional and magnetization transfer MRI study of the cervical cord in patients with MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Comparison of multiple sclerosis clinical subgroups using navigated spin echo diffusion-weighted imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Whole-brain diffusion MR histograms differ between MS subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Diffusion tensor magnetic resonance imaging in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Intra-voxel and inter-voxel coherence in patients with multiple sclerosis assessed using diffusion tensor MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis--a quantitative T1 relaxation time mapping approach.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Imaging axonal damage of normal-appearing white matter in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Cortical motor reorganization after a single clinical attack of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Evidence for widespread movement-associated functional MRI changes in patients with PPMS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Correlations between structural CNS damage and functional MRI changes in primary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

A functional magnetic resonance imaging study of patients with secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Low dose oral methotrexate treatment of multiple sclerosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970410-0

7 January 2021

10.1016/S1474-4422(06)70410-0

Identifiers

DOI

1 reference

2 August 2017

1 reference